Prelude Capital Management’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-5,023
| Closed | -$529K | – | 1452 |
|
|
2025
Q4 | $529K | Sell |
5,023
-5,515
| -52% | -$518K | 0.04% | 508 |
|
|
2025
Q3 | $884K | Buy |
10,538
+5,001
| +90% | +$412K | 0.07% | 335 |
|
|
2025
Q2 | $438K | Sell |
5,537
-596
| -10% | -$47.4K | 0.04% | 477 |
|
|
2025
Q1 | $550K | Sell |
6,133
-232
| -4% | -$21.7K | 0.04% | 476 |
|
|
2024
Q4 | $633K | Sell |
6,365
-12,283
| -66% | -$1.27M | 0.04% | 502 |
|
|
2024
Q3 | $2.12M | Buy |
18,648
+1,805
| +11% | +$214K | 0.13% | 209 |
|
|
2024
Q2 | $2.09M | Buy |
16,843
+13,401
| +389% | +$1.73M | 0.14% | 180 |
|
|
2024
Q1 | $454K | Sell |
3,442
-11,108
| -76% | -$1.37M | 0.02% | 676 |
|
|
2023
Q4 | $1.59M | Buy |
+14,550
| New | +$1.51M | 0.11% | 212 |
|
|
2022
Q4 | – | Sell |
-9,522
| Closed | -$820K | – | 1505 |
|
|
2022
Q3 | $820K | Buy |
+9,522
| New | +$850K | 0.03% | 478 |
|
|
2022
Q2 | – | Sell |
-2,980
| Closed | -$245K | – | 1970 |
|
|
2022
Q1 | $245K | Sell |
2,980
-16,647
| -85% | -$1.31M | 0.01% | 1167 |
|
|
2021
Q4 | $1.5M | Buy |
19,627
+14,464
| +280% | +$1.15M | 0.04% | 428 |
|
|
2021
Q3 | $388K | Buy |
+5,163
| New | +$393K | 0.01% | 1020 |
|
|
2021
Q2 | – | Sell |
-35,984
| Closed | -$2.66M | – | 1844 |
|
|
2021
Q1 | $2.66M | Buy |
35,984
+28,587
| +386% | +$2.11M | 0.07% | 253 |
|
|
2020
Q4 | $577K | Buy |
7,397
+4,711
| +175% | +$360K | 0.01% | 676 |
|
|
2020
Q3 | $213K | Sell |
2,686
-28,708
| -91% | -$2.25M | 0.01% | 667 |
|
|
2020
Q2 | $2.32M | Buy |
31,394
+31,227
| +18,699% | +$2.35M | 0.13% | 140 |
|
|
2020
Q1 | $12K | Sell |
167
-6,440
| -97% | -$506K | ﹤0.01% | 1098 |
|
|
2019
Q4 | $573K | Sell |
6,607
-2,060
| -24% | -$169K | 0.02% | 529 |
|
|
2019
Q3 | $696K | Sell |
8,667
-18,851
| -69% | -$1.51M | 0.03% | 437 |
|
|
2019
Q2 | $2.2M | Buy |
27,518
+14,269
| +108% | +$1.09M | 0.11% | 173 |
|
|
2019
Q1 | $1.05M | Sell |
13,249
-7,110
| -35% | -$532K | 0.06% | 321 |
|
|
2018
Q4 | $1.48M | Buy |
20,359
+965
| +5% | +$68.1K | 0.1% | 237 |
|
|
2018
Q3 | $1.31M | Buy |
19,394
+1,574
| +9% | +$100K | 0.08% | 294 |
|
|
2018
Q2 | $1.03M | Buy |
17,820
+5,567
| +45% | +$314K | 0.07% | 321 |
|
|
2018
Q1 | $637K | Buy |
+12,253
| New | +$662K | 0.05% | 380 |
|
|
2017
Q4 | – | Sell |
-29,063
| Closed | -$1.78M | – | 1585 |
|
|
2017
Q3 | $1.78M | Buy |
29,063
+18,402
| +173% | +$1.12M | 0.16% | 132 |
|
|
2017
Q2 | $652K | Buy |
10,661
+6,911
| +184% | +$421K | 0.06% | 285 |
|
|
2017
Q1 | $227K | Buy |
3,750
+2,515
| +204% | +$153K | 0.02% | 526 |
|
|
2016
Q4 | $69K | Buy |
+1,235
| New | +$72.3K | 0.01% | 950 |
|
|
2015
Q2 | – | Sell |
-2,360
| Closed | -$129K | – | 1914 |
|
|
2015
Q1 | $129K | Buy |
2,360
+1,102
| +88% | +$62.4K | 0.02% | 883 |
|
|
2014
Q4 | $68K | Sell |
1,258
-1,007
| -44% | -$56.1K | 0.01% | 1155 |
|
|
2014
Q3 | $128K | Buy |
2,265
+1,109
| +96% | +$62.3K | 0.02% | 967 |
|
|
2014
Q2 | $64K | Sell |
1,156
-535
| -32% | -$29.2K | 0.01% | 1274 |
|
|
2014
Q1 | $92K | Buy |
1,691
+1,628
| +2,584% | +$84.3K | 0.01% | 1043 |
|
|
2013
Q4 | $3K | Buy |
+63
| New | +$2.88K | ﹤0.01% | 1565 |
|
Other funds holding MRK
VCM
VPM
Prelude Capital Management's MRK Position: Q1 2026 in Review
Prelude Capital Management sold out of Merck (MRK) in Q1 2026, closing a stake of 5,023 shares — an estimated $529K sold.
Prelude Capital Management first reported a position in MRK in Q4 2013 and held it in 36 quarters. The position peaked at $2.66M in Q1 2021. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- Prelude Capital Management reported no remaining Merck position as of Q1 2026 after selling out during the quarter.
- Prelude Capital Management sold 5,023 Merck shares in Q1 2026, an estimated $529K.
- Prelude Capital Management first reported a position in Merck in Q4 2013 and held it in 36 quarters.
- Prelude Capital Management's Merck position peaked at $2.66M in Q1 2021.
- 3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.